Literature DB >> 19067662

Cardiac allograft remodeling after heart transplantation is associated with increased graft vasculopathy and mortality.

E Raichlin1, H R Villarraga, K Chandrasekaran, A L Clavell, R P Frantz, S S Kushwaha, R J Rodeheffer, C G McGregor, R C Daly, S J Park, W K Kremers, B S Edwards, N L Pereira.   

Abstract

The aim of this study was to assess the patterns, predictors and outcomes of left ventricular remodeling after heart transplantation (HTX). Routine echocardiographic studies were performed and analyzed at 1 week, 1 year and 3-5 years after HTX in 134 recipients. At each study point the total cohort was divided into three subgroups based on determination of left ventricle mass and relative wall thickness: (1) NG-normal geometry (2) CR-concentric remodeling and (3) CH-concentric hypertrophy. Abnormal left ventricular geometry was found as early as 1 week after HTX in 85% of patients. Explosive mode of donor brain death was the most significant determinant of CH (OR 2.9, p = 0.01) at 1 week. CH at 1 week (OR 2.72, p = 0.01), increased body mass index (OR 1.1, p = 0.01) and cytomegalovirus viremia (OR - 4.06, p = 0.02) were predictors of CH at 1 year. CH of the cardiac allograft at 1 year was associated with increased mortality as compared to NG (RR 1.87, p = 0.03). CR (RR 1.73, p = 0.027) and CH (RR 2.04, p = 0.008) of the cardiac allograft at 1 year is associated with increased subsequent graft arteriosclerosis as compared to NG.

Entities:  

Mesh:

Year:  2008        PMID: 19067662     DOI: 10.1111/j.1600-6143.2008.02474.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  8 in total

1.  The role of donor-specific antibodies in acute cardiac allograft dysfunction in the absence of cellular rejection.

Authors:  Nowell M Fine; Richard C Daly; Nisha Shankar; Soon J Park; Sudhir S Kushwaha; Manish J Gandhi; Naveen L Pereira
Journal:  Transplantation       Date:  2014-07-27       Impact factor: 4.939

2.  Recipient-derived EDA fibronectin promotes cardiac allograft fibrosis.

Authors:  Adam J Booth; Sherri C Wood; Ashley M Cornett; Alyssa A Dreffs; Guanyi Lu; Andrés F Muro; Eric S White; D Keith Bishop
Journal:  J Pathol       Date:  2012-01-04       Impact factor: 7.996

3.  Cardiac allograft hypertrophy is associated with impaired exercise tolerance after heart transplantation.

Authors:  Eugenia Raichlin; Malik A Al-Omari; Courtney L Hayes; Brooks S Edwards; Robert P Frantz; Barry A Boilson; Alfredo L Clavell; Richard J Rodeheffer; John A Schirger; Sudhir S Kushwaha; Thomas G Allison; Naveen L Pereira
Journal:  J Heart Lung Transplant       Date:  2011-05-31       Impact factor: 10.247

Review 4.  TGF-beta, IL-6, IL-17 and CTGF direct multiple pathologies of chronic cardiac allograft rejection.

Authors:  Adam J Booth; D Keith Bishop
Journal:  Immunotherapy       Date:  2010-07       Impact factor: 4.196

5.  Connective tissue growth factor promotes fibrosis downstream of TGFbeta and IL-6 in chronic cardiac allograft rejection.

Authors:  A J Booth; K Csencsits-Smith; S C Wood; G Lu; K E Lipson; D K Bishop
Journal:  Am J Transplant       Date:  2009-09-25       Impact factor: 8.086

6.  Critical role for IL-6 in hypertrophy and fibrosis in chronic cardiac allograft rejection.

Authors:  J A Diaz; A J Booth; G Lu; S C Wood; D J Pinsky; D K Bishop
Journal:  Am J Transplant       Date:  2009-06-16       Impact factor: 8.086

7.  TGFbeta neutralization within cardiac allografts by decorin gene transfer attenuates chronic rejection.

Authors:  Susan M Faust; Guanyi Lu; Sherri C Wood; D Keith Bishop
Journal:  J Immunol       Date:  2009-11-16       Impact factor: 5.422

8.  Antibody-mediated rejection 16 years post-cardiac transplantation: a case report of an uncommon late presentation in a middle-aged woman.

Authors:  Charles Miller; Knarik Arkun; David DeNofrio; Marwa Sabe
Journal:  Eur Heart J Case Rep       Date:  2019-09-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.